The Delhi High Court on Wednesday recorded Sun Pharmaceutical Industries Ltd.'s assurance that it will not sell its semaglutide-based drug in India until March 20, 2026, when Danish drugmaker Novo Nordisk's patent expires. Appearing before Justice Manmeet Pritam Singh Arora, the company also committed to exporting the drug only to countries where Novo does not hold patent rights....